Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation

International Journal of Cardiology

Volumn 148, Issue 1, 2011, Pages 96-101

  Gao, Fei ^a   Zhou, Yu Jie ^a   Wang, Zhi Jian ^a   Yang, Shi Wei ^a   Nie, Bin ^a   Liu, Xiao Li ^a   Jia, De An ^a   Yan, Zhen Xian ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Dual antiplatelet therapy; Percutaneous coronary intervention; Triple antithrombotic therapy; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CORONARY STENT; DEATH; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE THROMBUS; HUMAN; INCIDENCE; INTRACARDIAC THROMBOSIS; LONG TERM CARE; LUNG EMBOLISM; META ANALYSIS; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE; TREATMENT OUTCOME; WARFARIN;

EID: 79952816422     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.11.019     Document Type: Article

References (32)

1. King III SB, Smith Jr SC, Hirshfeld Jr JW, Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008;51:172-209.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2006;27:1979-2030. (Pubitemid 44313588)
3. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen J, Cuisset T, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010;103(1):13-28.
4. ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
5. Rubboli A, Halperin JL. Pro: "Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions". Thromb Haemost 2008;100(5):752-3.
6. Roldán V, Marín F. Contra: "Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions". Not for everybody. Thromb Haemost 2008;100(5):754-5.
7. Ruiz-Nodar JM, Marín F, Manzano-Fernández S, Valencia-Martín J, Hurtado JA, Roldán V, et al. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation undergoing percutaneous coronary revascularization. Chest 2010 [Epub ahead of print].
8. Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010;103(4):833-40.
9. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE-W): a randomized controlled trial. Lancet 2006;367:1903-12.
10. Apostolakis S, Shantsila E, Lip GY, Lane DA. Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". Thromb Haemost 2009;102(5):914-5.
11. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170(16):1433-41.
12. Karjalainen Pasi P, Porela Pekka, Ylitalo Antti, Vikman Saila, Nyman Kai, Vaittinen Mari-Anne, et al. Safety and efficacy of combined antiplatelet - warfarin therapy after coronary stenting. Eur Heart J 2007;28:726-32.
13. Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004;147:463-7. (Pubitemid 38880866)
14. Manzano-Fernández S, Pastor FJ, Marín F, Cambronero F, Caro C, Pascual-Figal DA, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008;134(3):559-67.
15. Konstantino Y, Iakobishvili Z, Porter A, Sandach A, Zahger D, Hod H, et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 2006;105(2):80-5. (Pubitemid 43189779)
16. DeEugenioD,Kolman L,DeCaroM, Andrel J, Chervoneva I,Duong P, et al.Risk ofmajor bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007;27:691-6. (Pubitemid 46700961)
17. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, et al. Longterm outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008;102(12):1618-23.
18. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from stenting and oral anticoagulants [STENTICO]). Am J Cardiol 2009;104:338-42.
19. Ruiz-Nodar JM, Marín F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008;51(8):818-25. (Pubitemid 351255616)
20. Nguyen MC, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007;28(14):1717-22.
21. Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006;18:162-4. (Pubitemid 44576090)
22. Mattichak SJ, Reed PS, Gallagher MJ, Boura JA, O'Neill WW, Kahn JK. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol 2005;18:163-6. (Pubitemid 40942726)
23. Rubboli A, Milandri M, Castelvetri C, Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 2005;104(2):101-6.
24. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of the drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91. (Pubitemid 44881238)
25. Brar SS, Kim J, Brar SK, Zadegan R, Ree M, Liu IL, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 2008;51:2220-7. (Pubitemid 351754993)
26. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68. (Pubitemid 46089732)
27. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9. (Pubitemid 46376803)
28. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-97. (Pubitemid 46376799)
29. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-778.
30. Airaksinen KEJ, Ylitalo A, Karjalainen PP. Drug-eluting stents in patients on longterm oral anticoagulation therapy: a mission impossible? Interv Cardiol 2010;2:127-35.
31. Ruiz-Nodar JM, Marín F, Sánchez-Payá J, Hurtado JA, Valencia-Martín J, Manzano-Fernández S, et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 2009 Apr;30(8):932-9.
32. Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.